As of 30 Sep 2025, 59 institutional investors reported holding $726,382,500 in principal (par value) of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $26,000 | $28,879 | +$17,701 | 109.94% | 2 |
| 2025 Q3 | $726,382,500 | $834,806,788 | +$51,986,123 | 114.78% | 59 |
| 2025 Q2 | $728,633,184 | $728,093,254 | +$9,554,283 | 99.57% | 64 |
| 2025 Q1 | $707,502,041 | $750,571,965 | -$21,159,131 | 105.81% | 57 |
| 2024 Q4 | $713,351,051 | $682,649,196 | +$31,068,637 | 95.39% | 57 |
| 2024 Q3 | $685,548,882 | $688,251,428 | -$133,839,090 | 100.08% | 53 |
| 2024 Q2 | $832,977,781 | $795,652,096 | +$12,847,172 | 95.33% | 57 |
| 2024 Q1 | $818,788,507 | $726,986,623 | -$742,682 | 88.67% | 60 |
| 2023 Q4 | $184,275,000 | $160,208,685 | 86.94% | 1 | |
| 2023 Q3 | $614,839,599 | $523,001,963 | +$8,635,165 | 84.54% | 63 |
| 2023 Q2 | $606,758,832 | $506,221,139 | +$19,224,781 | 83.3% | 64 |
| 2023 Q1 | $648,973,068 | $551,296,682 | +$84,295,094 | 84.78% | 61 |
| 2022 Q4 | $485,073,723 | $487,941,731 | +$18,531,103 | 97.13% | 54 |
| 2022 Q3 | $478,505,894 | $386,404,004 | -$210,925,529 | 84.92% | 47 |
| 2022 Q2 | $712,503,349 | $599,937,258 | +$140,414,664 | 88.34% | 50 |
| 2022 Q1 | $542,664,884 | $460,363,225 | +$460,360,646 | 87.69% | 45 |